Skip to main content

Weather Alert

Hurricane activity is severely impacting Quest locations across the Southeast. We ask that patients please double check your appointment status to ensure your designated Patient Service Center is operational.

Hide

Nuclear NR4A2 (Nurr1) Immunostaining is a Novel Marker for Acinic Cell Carcinoma of the Salivary Glands Lacking the Classic NR4A3 (NOR-1) Upregulation

Nuclear NR4A2 (Nurr1) Immunostaining is a Novel Marker for Acinic Cell Carcinoma of the Salivary Glands Lacking the Classic NR4A3 (NOR-1) Upregulation.

Authors: Haller F, Moskalev EA, Kuck S, Bieg M, Winkelmann C, Müller SK, Ihrler S, Märkl B, Eils R, Wiemann S, Iro H, Hartmann A, Agaimy A.

Am J Surg Pathol. 2020 Apr. doi: 10.1097/PAS.0000000000001494. [Epub ahead of print]

Disclaimer: One or more of the authors of this publication were employed at the time by DermPath, a subsidiary of Quest Diagnostics.

Specialties: Oncology, Dermatology